BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35649138)

  • 1. Curcumin-induced antitumor effects on triple-negative breast cancer patient-derived xenograft tumor mice through inhibiting salt-induced kinase-3 protein.
    Cheng TC; Sayseng JO; Tu SH; Juan TC; Fang CL; Liao YC; Chu CY; Chang HW; Yen Y; Chen LC; Ho YS
    J Food Drug Anal; 2021 Dec; 29(4):622-637. PubMed ID: 35649138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation.
    Pai JT; Chen XH; Leu YL; Weng MS
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tea polyphenol epigallocatechin-3-gallate inhibits cell proliferation in a patient-derived triple-negative breast cancer xenograft mouse model via inhibition of proline-dehydrogenase-induced effects.
    Lee WJ; Cheng TC; Yen Y; Fang CL; Liao YC; Kuo CC; Tu SH; Lin LC; Chang HW; Chen LC; Ho YS
    J Food Drug Anal; 2021 Mar; 29(1):113-127. PubMed ID: 35696218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
    Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
    Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
    Lou L; Yu Z; Wang Y; Wang S; Zhao Y
    Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
    Liu L; Fu Y; Zheng Y; Ma M; Wang C
    Phytomedicine; 2020 Nov; 78():153312. PubMed ID: 32866906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
    Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
    J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway.
    Wang G; Duan P; Wei Z; Liu F
    Mol Biol Rep; 2022 Apr; 49(4):3259-3270. PubMed ID: 35076853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.
    Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J
    Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
    Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
    Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
    Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
    BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
    Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
    J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Linolenic acid inhibits the migration of human triple-negative breast cancer cells by attenuating Twist1 expression and suppressing Twist1-mediated epithelial-mesenchymal transition.
    Wang SC; Sun HL; Hsu YH; Liu SH; Lii CK; Tsai CH; Liu KL; Huang CS; Li CC
    Biochem Pharmacol; 2020 Oct; 180():114152. PubMed ID: 32679125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells.
    Jagadish N; Gupta N; Agarwal S; Parashar D; Sharma A; Fatima R; Topno AP; Kumar V; Suri A
    Tumour Biol; 2016 Oct; 37(10):13101-13110. PubMed ID: 27449044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.